PredictImmune has welcomed Tim Rea to its board as a non-executive director, with immediate effect.
Tim has been active in the venture capital and start-up ecosystem for over 20 years across a broad range of sectors, stages and geographies. He is particularly passionate about the application of new, disruptive technologies into the healthcare and life sciences ecosystems.
An investor at BGF, the UK and Ireland’s most active investor in growing businesses, Tim has supported the process of expanding BGF’s support for the life sciences sector, working across its 14 regional offices and with a focus on diagnostics. PredictImmune is BGF’s eighth life sciences investment in the last 12 months.
Paul Kinnon, CEO, PredictImmune added that he is "delighted" to welcome Tim to the board.
He continued, "His experience as an active investor in diagnostics and belief in the ability of key diagnostic breakthroughs that enable a more personalised approach to treatment, to drive exciting life science developments is a perfect fit with PredictImmune’s mindset and objectives. We are looking forward to Tim’s input as we push towards our goal of enabling improved treatment choice in patients diagnosed with debilitating diseases such as IBD.”